Saponin-Based Adjuvants Global Market Report 2026

The saponin-based adjuvants market size has grown rapidly in recent years. It will grow from $1.17 billion in 2025 to $1.3 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing vaccine research activities, rising demand for effective adjuvants, growth of human and veterinary vaccines, advancements in plant-based extraction techniques, regulatory support for adjuvant development.

The saponin-based adjuvants market size is expected to see rapid growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to adoption of synthetic and semi-synthetic saponin analogues, integration with next-generation vaccine platforms, expansion of veterinary vaccine applications, increasing r&d investments in immunology, focus on personalized and precision vaccine strategies. Major trends in the forecast period include development of novel saponin formulations, enhanced vaccine immunogenicity, adjuvant dose sparing strategies, integration with mrna and protein-based vaccines, standardization and quality control improvements.

The growing demand for vaccine development activities is expected to drive the growth of the Saponin-Based Adjuvants market in the coming years. Vaccine development activities encompass the research, clinical testing, regulatory approval, and commercialization processes undertaken to create new or improved vaccines for both infectious and non-infectious diseases. Governments and international health organizations are intensifying vaccine development activities due to ongoing funding commitments for infectious disease prevention and pandemic preparedness. Saponin-Based Adjuvants facilitate vaccine development by improving antigen immunogenicity, enabling dose reduction, and enhancing cellular immune responses in next-generation vaccine formulations. For example, in April 2025, according to the World Health Organization, a Switzerland-based international public health organization, global measles cases were estimated at 10.3 million in 2023, reflecting an approximate 20% increase compared to 2022, underscoring the growing necessity for expanded vaccine development and immunization initiatives. Consequently, the rising demand for vaccine development activities is fueling the growth of the Saponin-Based Adjuvants market.

Leading companies operating in the saponin‑based adjuvants market are focusing on developing sustainable and scalable manufacturing alternatives, such as cultured plant cell-derived QS-21, to ensure supply chain stability, consistent quality, and reduced dependence on natural resources. Cultured plant cell-derived QS-21 refers to an advanced production method where the key vaccine adjuvant is grown from plant cells in a controlled laboratory setting, rather than being extracted from the bark of rare trees. For example, in August 2024, SaponiQx, a US-based biomanufacturing company, launched STIMULON cultured plant cell QS-21, a cpcQS-21 adjuvant available for commercial purchase through InvivoGen. This product is produced via plant cell culture rather than tree bark, ensuring consistent and scalable supply; it offers high purity, lot-to-lot uniformity, and reduced environmental impact. Functionally, STIMULON cpcQS-21 retains the same immunostimulatory potency as tree-derived QS-21 in driving both humoral and cellular immune responses, making it suitable for use in vaccines for infectious diseases such as malaria, shingles, and RSV.

In October 2023, SPI Pharma Inc., a US-based pharmaceutical company, entered into a partnership with Q Vant Biosciences Inc. for an undisclosed sum. Through this collaboration, SPI Pharma intends to broaden the production and global distribution of sustainable, scalable, pharmaceutical-grade saponin adjuvants, thereby improving vaccine formulation capabilities. Q‑Vant Biosciences, Inc. is a US-based biotechnology company that focuses on the sustainable production, purification, and supply of Quillaja saponin‑based adjuvants for both human and veterinary vaccines.

Major companies operating in the saponin-based adjuvants market are GlaxoSmithKline plc, Croda International plc, HIPRA Human Health S.L, Novavax, Inc., Seppic S.A., Merck KGaA, Agenus Inc., PhytoLab GmbH & Co. KG, SPI Pharma Inc., InvivoGen, Desert King International, Adjuvatis S.A.S., Aphios Corporation, Vaxine Pty Ltd, Fatro S.p.A., Q-Vant Biosciences, AVT Pharmaceutical Inc., SaponiQx.

North America was the largest region in the saponin-based adjuvants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the saponin-based adjuvants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the saponin-based adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The saponin-based adjuvants market consists of sales of plant-derived saponins, combination adjuvant systems, VSA® adjuvants, saponin-liposome formulations, saponin-nanoparticle adjuvants, Fraction C saponins, and custom saponin blends. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Saponin-based adjuvants are naturally occurring compounds, primarily extracted from plants, that enhance the immune response to an antigen. They work by activating both humoral and cellular immunity, boosting the strength and duration of immune responses. These adjuvants are highly valued for increasing immunogenicity, allowing dose reduction, and improving formulation performance.

The primary product types of saponin-based adjuvants include purified Quillaja saponin extracts, QS-21 saponin fractions, crude saponin extracts, semi-purified saponin blends, and synthetic and semi-synthetic saponin analogues. Purified Quillaja saponin extracts are compounds derived from the bark of Quillaja saponaria that enhance immune responses in vaccines and immunotherapies. They are sourced from Quillaja saponaria, soybean, and other origins, and formulated as particulate, emulsion, liposomal, and other preparations. Applications include human vaccines, veterinary vaccines, research applications, and others, serving pharmaceutical companies, research institutes, contract research organizations, and other end-users.

Tariffs have influenced the saponin-based adjuvant market by increasing the cost of imported purified extracts, synthetic analogues, and formulation components. This has primarily impacted segments such as purified quillaja extracts and synthetic saponin analogues in regions including North America and Europe, which depend on imports for high-quality materials. While posing challenges in cost and supply chain delays, tariffs have encouraged local production, innovation in semi-synthetic saponin development, and diversification of sourcing strategies, potentially enhancing market resilience.

The saponin-based adjuvants market research report is one of a series of new reports that provides saponin-based adjuvants market statistics, including saponin-based adjuvants industry global market size, regional shares, competitors with a saponin-based adjuvants market share, detailed saponin-based adjuvants market segments, market trends and opportunities, and any further data you may need to thrive in the saponin-based adjuvants industry. This saponin-based adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.